MRNA is trading 5.5% higher at $63.01 after investors reacted positively to the company's Science Day presentation detailing its expansion into autoimmune and oncology treatments.
- Moderna showcased its new in vivo CAR-T program, mRNA-6007, as part of a deepening pipeline beyond traditional vaccines into next-generation immune applications.
- The stock is significantly outperforming broader indices, which are trading lower, as market attention shifts toward the company's diversified clinical prospects.